Inventor

Jean E. F. Rivier

Inventor

La Jolla, CA, US

Overview

1978–2019

Patent span

Human necessities

Primary field (CPC A)

Patents· 132 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C07Kprimary

C07KPeptides31%

A61KPreparations for medical, dental or toiletry purposes29%

Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests16%

A61PSpecific therapeutic activity of chemical compounds or medicinal preparations12%

G01NInvestigating or analysing materials by determining their chemical or physical properties3%

C07CAcyclic or carbocyclic compounds2%

C07DHeterocyclic compounds2%

A23KFodder1%

Y02PClimate change mitigation technologies in the production or processing of goods1%

C12NMicroorganisms or enzymes1%

PatentTitleYear

10,166,271Methods for promoting hair growth2019 9,572,866'Urocortin 2 analogs and uses thereof'2017 9,388,229'Urocortin-III and uses thereof'2016 9,035,022'Cyclic CRF antagonist peptides'2015 8,691,761'Somatostatin receptor 2 antagonists'2014 8,669,092'Urocortin-III and uses thereof'2014 8,501,687'Receptor(SSTR2)-selective somatostatin antagonists'2013 8,445,425'Urocortin-III and uses thereof'2013 8,084,413'Urocortin-III and uses thereof'2011 8,044,025'Urocortin proteins and uses thereof'2011 7,960,342'Receptor(SSTR2)-selective somatostatin antagonists'2011 7,869,958'Structure-based modulators of B1 G-protein coupled receptors'2011 7,851,588'CRFR1 selective ligands'2010 7,638,607'Urocortin proteins and uses thereof'2009 7,498,300'CRFR1 selective ligands'2009 7,459,427'Urocortin-III and uses thereof'2008 7,238,775'Receptor(SSTR4)-selective somatostatin analogs'2007 7,223,846'Urocortin proteins and uses thereof'2007 7,141,546'CRFR2 selective ligands'2006 RE039240'Conotoxins I'2006 7,019,109'SSTR1-selective analogs'2006 6,953,838'Urocortin-III and uses thereof'2005 6,838,274'Urocortin proteins and uses thereof'2005 6,747,125'Peptides intermediates for making GnRH antagonists'2004 6,579,967'Receptor-selective somatostatin analogs'2003 6,515,103'Conantokins'2003 6,326,463'Cyclic CRF agonists'2001 6,323,312'Cyclic CRF antagonist peptides'2001 6,214,797'Urocortin peptides, nucleic acid encoding same methods for using same'2001 5,969,096'Conotoxin peptides'1999 5,874,227'Cyclic CRF antagonists'1999 5,844,074'Cyclic CRF agonists'1998 5,824,771'Cyclic CRF agonists'1998 5,807,986'Methods of making and screening betide libraries'1998 5,807,983'GNRH antagonist betides'1998 5,777,073'Cyclic CRF antagonist peptides'1998 5,750,499'Receptor-selective somatostatin analogs'1998 5,744,450'GnRH analogs'1998 5,710,249'Amino acids and processes for making peptides using same'1998 5,700,778'Conotoxins I'1997 5,681,928'Betides and methods for screening peptides using same'1997 5,663,292'Cyclic CRF analogs'1997 5,643,877'Compounds comprising gonadotropin releasing hormone (GnRH) and methods for controlling reproduction in fish'1997 5,580,957'GnRH analogs'1996 5,569,742'Centrally truncated NPY cyclic peptides'1996 5,565,574'Preparation of phenylalanine derivatives bearing a 1,2,4-triazole moiety and their use in peptides'1996 5,530,095'Peptides of melanin concentrating hormone precursor'1996 5,510,458'CRF antagonists'1996 5,506,207'GNRH antagonists XIII'1996 5,493,006'Cyclic CRF analogs'1996 5,449,766'DNA encoding NEI and NGE peptides'1995 5,439,885'CRF analogs'1995 5,432,155'Conotoxins I'1995 5,371,070'Bicyclic GnRH antagonists and a method for regulating the secretion of gonadotropins'1994 5,352,796'Amino acids useful in making GnRH analogs'1994 5,328,899'NPY peptide analogs'1994 5,296,468'GnRH analogs'1994 5,278,146'CRF analogs'1994 5,262,519'GRF analogs XI'1993 5,245,009'CRF antagonists'1993 5,235,036'CRF analogs'1993 5,169,932'GnRH analogs'1992 5,169,935'Method of making peptides'1992 5,132,111'CRF analog conjugates'1992 5,112,809'CRF analogs'1992 5,109,111'CRF antagonists'1992 5,098,995'GRF Analogs VIIA'1992 5,064,939'Cyclic GnRH antagonists'1991 5,049,655'Melanin-concentrating hormones'1991 5,043,322'Cyclic GRF analogs'1991 5,032,507'Potentiation of erythropoiesis'1991 5,026,685'NPY peptide analogs'1991 5,015,729'Ovine inhibin'1991 5,002,931'GRF analogs VII'1991 4,973,577'FSH-releasing peptides'1990 4,908,352'Urotensin peptides'1990 4,864,019'Antibodies to inhibin and conjugates produced therefrom'1989 4,843,064'GRF analogs V'1989 4,784,987'GRF analogs VI'1988 4,740,500'GnRH antagonists VIII'1988 4,737,578'Human inhibin'1988 4,728,726'GRF analogs IIIb'1988 4,703,035'Human pancreatic GRF amidated fragments'1987 4,701,499'Synthesis of N-substituted peptide amides'1987 4,689,396'GnRH antagonists V'1987 4,677,193'Peptides containing an aliphatic-aromatic ketone side chain'1987 4,661,472'GnRH antagonists IX'1987 4,652,550'GnRH antagonists VII'1987 4,628,043'Hypothalamic GRF agonists'1986 4,626,523'GRF analogs II'1986 4,619,914'GNRH antagonists IIIB'1986 4,605,642'CRF antagonists'1986 4,595,676'Rat hypothalamic GRF'1986 4,594,329'CRF analogs'1986 4,569,927'GnRH Antagonists IV'1986 4,569,967'Synthesis of N-substituted peptide amides'1986 4,565,804'GnRH Antagonists VI'1986 4,563,352'Human pancreatic GRF'1986 4,530,838'Synthetic calcitonin-gene-related peptides for lowering blood pressure or gastric acid secretion in mammals'1985 4,529,595'GRF Analogs'1985 4,528,190'GRF Analogs IV'1985 4,528,189'Urotensin peptides'1985 4,518,586'GRF Analogs III'1985 4,490,364'CCK Agonists II'1984 4,489,061'Treatment of male mammals'1984 4,489,163'rCRF and analogs'1984 4,447,356'Conotoxins'1984 4,444,759'GnRH Antagonists II'1984 4,444,682'Method of sulfation'1984 4,443,368'Peptides affecting gonadal function'1984 4,428,942'Analogs of somatostatin'1984 4,415,558'CRF And analogs'1983 4,410,514'GnRH Agonists'1983 4,409,208'GnRH antagonists'1983 4,393,050'Analogs of extended N-terminal somatostatin'1983 4,386,074'LRF Antagonists'1983 4,382,922'Peptides affecting gonadal function'1983 4,377,482'Mobile phase for liquid chromatography'1983 4,377,574'Contraceptive treatment of male mammals'1983 4,372,884'Pharmaceutically active peptides'1983 4,331,661'Bombesin analogs'1982 4,307,083'LRF Antagonists'1981 4,292,313'LRF Antagonists'1981 RE030548'Peptides which effect release of hormones'1981 4,244,946'Water-soluble peptides affecting gonadal function'1981 4,218,439'Peptide which inhibits gonadal function'1980 4,216,141'Method for cyclization of peptides'1980 4,215,038'Peptides which inhibit gonadal function'1980 4,211,693'Peptides with para-substituted phenylalanine'1980 4,207,311'Peptides having analgesic and thermoregulative properties'1980 4,133,782'Somatostatin analogs with dissociated biological activities'1979 4,105,603'Peptides which effect release of hormones'1978

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1978–2019Patents assigned to SALK INST FOR BIOLOGICAL STUDI (112)· patent assignee history

1978–2019Based in La Jolla, CA, US· patent location history

1984–2015Patents assigned to RIVIER JEAN E F (4)· patent assignee history

1985–1997Based in LaJolla, CA, US· patent location history

1991–2019Patents assigned to UNIV CALIFORNIA (4)· patent assignee history

1995–2003Patents assigned to UNIV UTAH RES FOUND (4)· patent assignee history

2005–2017Patents assigned to RES DEV FOUNDATION (12)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees

Assignee	Patents	Span
SALK INST FOR BIOLOGICAL STUDI	112	1978–2019
RES DEV FOUNDATION	12	2005–2017
RIVIER JEAN E Fself	4	1984–2015
UNIV CALIFORNIA	4	1991–2019
UNIV UTAH RES FOUND	4	1995–2003

Locations

Location	Patents	Span
La Jolla, California, US	126	1978–2019
LaJolla, California, US	6	1985–1997